Grail says FDA advisory panel meets Sept. 23 on Galleri test PMA review
Reuters2026/08/07 15:05- Grail faces an FDA advisory committee review on Sept. 23, 2026 for its Galleri multi-cancer early detection blood test PMA.
- The PMA was submitted on Jan. 29, 2026. The FDA granted Galleri Breakthrough Device designation in 2018.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Responding to the “hate wave” against data centers, Trump: Americans who oppose will “eventually fall behind and become poor”
US President Trump has publicly endorsed the construction of data centers and warned that slowing down AI infrastructure development would allow other countries to surpass the US. However, due to electoral pressures, many within the Republican Party have turned against these projects, with legislators in multiple states halting related initiatives. So far, dozens of data center projects across the country have been suspended due to local opposition, involving investments of approximately $150 billions.
BJ’s Restaurants director Bradford Richmond acquires 753 common shares worth $47,637.25
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
